TAD
7.12.2020 13:33:04 CET | Business Wire | Press release
Toyama Prefectural Museum of Art and Design is inviting entries for “The 13th International Poster Triennial in Toyama 2021” (IPT2021), the only poster exhibition in Japan opens to international entries, held once every three years. Due to the spread of COVID-19, and considering the overseas mail situation, we decided on November 13, 2020 to extend the deadline for entries to February 28, 2021 (Sun.).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201206005062/en/
IPT2021 is an exhibition showcasing posters chosen from throughout the world, designed to provide a review of the current state and achievements in international poster design. It is scheduled to be held from mid-July to early September 2021.
In addition to paper-format entries for Categories A and B, we have expanded the digital-data category for young designers introduced at the last IPT to create a “U30+Student Category” accepting entries from students aged 30 or older.
Details of Entry Guidelines are posted on the IPT2021 page on our Museum’s website.
Special IPT2021 webpage: https://tad-toyama.jp/en/ipt
[
Entry Categories]
*For details, please consult the Entry Guidelines.
Category A
Paper-format posters. No fixed theme. (Open to both client works and independent works. Posters created in or after May 2018.)
Category B
Paper-format posters. Independent works on the theme “INVISIBLE.”
U30+Student
[
Expanded entry from this IPT]
Open to entries from participants aged 30 or younger (born in 1990 or later), or students currently enrolled in an educational institution (students aged 30 or older can enter).
Entries submitted as digital data. Independent works on the theme “INVISIBLE.”
[
Period for submitting entries]
September 1, 2020 (Tues.) - arriving no later than February 28, 2021 (Sun.)
*Extended from original deadline of December 10, 2020 (Thurs.)
*In the event of any changes in schedule, etc. of IPT2021 due to the spread of COVID-19, we will notify you on the IPT2021 page (https://tad-toyama.jp/en/ipt ) on our Museum’s website.
About Toyama Prefectural Museum of Art and Design (TAD)
We introduce world-class collections from new perspectives, with original themes and presentation styles. We offer programs where you can make new discoveries on each visit, actively incorporating design viewpoints in response to this new era. Our goal is to be a platform connecting people to art and design.
Renowned architects and designers have contributed greatly, with Hiroshi Naito responsible for architectural design, Kazumasa Nagai for our logo, Issey Miyake for designing uniforms, and Taku Satoh designed posters announcing the opening of the Museum.
https://tad-toyama.jp/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20201206005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
